G1 Therapeutics (GTHX) Downgraded by BidaskClub to Hold

BidaskClub downgraded shares of G1 Therapeutics (NASDAQ:GTHX) from a buy rating to a hold rating in a report published on Saturday morning.

A number of other equities analysts also recently commented on the company. BTIG Research began coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They set a buy rating and a $38.00 price objective on the stock. Cowen reiterated a buy rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. Finally, Zacks Investment Research downgraded G1 Therapeutics from a hold rating to a sell rating in a research report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Buy and an average price target of $31.40.

Shares of G1 Therapeutics (GTHX) traded down $0.34 during trading on Friday, reaching $22.97. The company had a trading volume of 36,335 shares, compared to its average volume of 72,850. G1 Therapeutics has a 52-week low of $12.04 and a 52-week high of $28.67.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.55) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.01. analysts forecast that G1 Therapeutics will post -2.72 EPS for the current year.

In other G1 Therapeutics news, Director Fredric N. Eshelman bought 250,000 shares of G1 Therapeutics stock in a transaction on Monday, November 13th. The shares were bought at an average price of $19.73 per share, for a total transaction of $4,932,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajesh Malik sold 3,776 shares of G1 Therapeutics stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $22.96, for a total value of $86,696.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 545,932 shares of company stock worth $10,848,385.

A number of large investors have recently bought and sold shares of GTHX. FMR LLC purchased a new stake in G1 Therapeutics in the second quarter valued at $34,093,000. Vanguard Group Inc. purchased a new stake in G1 Therapeutics in the second quarter valued at $1,291,000. Goldman Sachs Group Inc. purchased a new stake in G1 Therapeutics in the second quarter valued at $1,144,000. Bank of New York Mellon Corp purchased a new stake in G1 Therapeutics in the third quarter valued at $568,000. Finally, Emerald Advisers Inc. PA raised its position in G1 Therapeutics by 2.5% in the third quarter. Emerald Advisers Inc. PA now owns 728,433 shares of the company’s stock valued at $18,131,000 after purchasing an additional 17,977 shares during the period. Institutional investors own 43.25% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “G1 Therapeutics (GTHX) Downgraded by BidaskClub to Hold” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/04/g1-therapeutics-gthx-downgraded-by-bidaskclub-to-hold.html.

About G1 Therapeutics

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply